Ildong Pharmaceutical Group Pursues Partnering Activities at 'BIO-Europe' Including 'GLP-1RA Obesity Drug'

Ildong Pharmaceutical Group announced on November 3 that it will participate in the '2025 BIO-Europe,' where it will showcase its new drug pipeline and pursue business activities such as partnering meetings.

'BIO-Europe' is the largest academic and business exchange event in Europe related to the pharmaceutical and biotechnology industries. This year's event is being held in Vienna, Austria, through November 5.

The headquarters of Ildong Pharmaceutical Group in Seocho-gu, Seoul. Ildong Pharmaceutical Group

According to Ildong Pharmaceutical Group, during the event, the company plans to explore collaboration opportunities related to new drug commercialization-including research and development and licensing out (technology transfer)-with numerous overseas companies, including global partners.

Ildong Pharmaceutical Group and Unovia will hold partnering meetings regarding 'ID110521156,' a GLP-1 RA (glucagon-like peptide-1 receptor agonist) targeting obesity and diabetes, as well as 'padoprazan,' a P-CAB (potassium-competitive acid blocker) class treatment for peptic ulcers.

ID110521156 is an orally administered synthetic new drug candidate based on a small molecule compound. Compared to existing peptide injectables, it offers differentiated features in terms of pharmacological properties, manufacturing efficiency and cost-effectiveness, and user convenience.

In particular, the drug profile maintains effective blood concentration for over 18 hours without accumulation in the body, making it ideal for commercialization as an oral (taken by mouth) treatment that can be administered once daily over a long period.

In Phase 1 clinical trials completed last month, ID110521156 demonstrated up to 13.8% weight loss over four weeks and showed a favorable safety profile without significant adverse events such as gastrointestinal disorders or hepatotoxicity, which are common side effects of existing treatments.

Padoprazan, a P-CAB formulation, is currently being co-developed in Korea with Daewon Pharmaceutical. The drug has recently entered Phase 3 clinical trials to evaluate its efficacy and safety in patients with erosive and non-erosive gastroesophageal reflux disease.

Idience, a subsidiary specializing in the development of anticancer drugs, will present its oncology pipeline, including the PARP inhibitor venadaparib, the pan-KRAS inhibitor 'ID12241,' and a dual payload ADC (antibody-drug conjugate).

Venadaparib has received Orphan Drug Designation (ODD) from the U.S. FDA and is currently undergoing a variety of studies, including a Phase 2a combination therapy trial for gastric cancer in Korea and the United States. In September, the company signed a licensing-out agreement worth 70 billion won for the EAEU (Eurasian Economic Union) and GCC (Gulf Cooperation Council) regions.

A representative from Ildong Pharmaceutical Group stated, "During the event, in addition to pre-arranged partnering meetings for each subsidiary and pipeline, we plan to continue various activities, including discussions on collaboration to create global business opportunities such as new drug commercialization."

This content was produced with the assistance of AI translation services.